MusclePharm And Munster Rugby Form Strategic Partnership

DENVER, April 18, 2017 /PRNewswire/ -- MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, announced today that it has formed a three-year strategic partnership with Munster Rugby, Ireland's leading professional provincial rugby team and two-time winners of the European Rugby Champions Cup.

(PRNewsfoto/MusclePharm Corporation)

MusclePharm harbors existing partnerships with other world-class sporting organizations, including New Zealand's premier rugby outfit and current Super Rugby champions the Hurricanes. Under the terms of this latest agreement, MusclePharm will serve as the official sports nutrition partner to Munster Rugby. The team will be exclusively supplied with MusclePharm's superior sports nutrition and post-workout recovery supplements which have been certified by Informed-Choice as containing no banned substances. MusclePharm's branding will be prominently featured throughout a number of channels including product integration, promotional training sessions, sampling days, print media, online digital activity and in-stadia assets at Munster Rugby's home stadiums of Thomond Park and Irish Independent Park.

As Ireland's preeminent provincial rugby team with a rich heritage of more than 130 years, Munster Rugby has a loyal and expansive international following that enables MusclePharm to significantly enhance its global brand visibility. The team's dedicated fan base spans several continents, with millions of viewers worldwide tuning in to Munster's televised games each year.

"Entering into this partnership with Munster Rugby underscores our commitment to serving athletes of all types and all levels with outstanding nutritional supplement products, free of banned substances, that complement their sports and lifestyle, while simultaneously furthering our global expansion goals," said Ryan Drexler, CEO, MusclePharm. "MusclePharm currently boasts a strong brand presence in Europe and, by partnering with Munster Rugby, we have a unique opportunity to reach an exceptionally engaged audience in Europe and beyond. Furthermore, the addition of another professional sports team to our user base serves to showcase our products' efficacy and ability to adequately support the demanding lifestyles of dedicated athletes everywhere."

"Partnering with MusclePharm makes perfect sense for both our players and fans," said Enda Lynch, Munster's Head of Commercial & Marketing. "MusclePharm is a brand known for its high-quality ingredients, commitment to label transparency and – most notably – the results it helps athletes achieve. We look forward to working closely with the company in a number of areas to provide meaningful brand experiences."

Munster Rugby participates in both the Pro12 and European Rugby Champions Cup, and will face defending champions Saracens in the prestigious European Rugby Champions Cup semi-finals in Dublin on April 22nd 2017. This match will be televised across five continents.

MusclePharm® is a scientifically-driven, performance lifestyle company that develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. Its portfolio of recognized brands includes MusclePharm® Sport Series, Black Label and Core Series, FitMiss™, as well as Natural Series which was launched in 2017. These products are available in more than 120 countries and over 50,000 retail outlets worldwide. The clinically-proven supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition industry. For more information, visit http://www.musclepharm.com. To sign up to receive MusclePharm news via email, please visit http://ir.musclepharmcorp.com/email-alerts.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, the Company's Quarterly Reports on Form 10-Q and other filings submitted by the Company to the Securities and Exchange Commission, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.